Wall Street equity analysts frequently evaluate Labcorp Holdings (NYSE: LH) as a defensive healthcare holding due to its stable, recurring demand for clinical diagnostic testing, strong free cash flow generation, and strategic expansion into specialized oncology and biopharmaceutical central laboratory services. Long-term investors often favor the stock for its defensive characteristics during broader economic downturns, though prospective buyers must weigh labor cost pressures and reimbursement rate changes.